Characterization of Tau vaccines identifies diverse antibody binding profiles and efficacy, demonstrating that specific forms of Tau can be targeted by vaccines with subsequent functional impact.

Immunotherapy has become a tractable path for Alzheimer’s disease therapies. One of the impediments of these therapies is their intrinsic limitation of targeting, particularly regarding Tau. It is unclear to what degree these therapies target the specific disease‐causing Tau form in each individual patient at the required time in disease progression. To address these challenges, Vaxxinity is developing a vaccine derived immunotherapy targeting Tau.